8-KMaterial AgreementsExhibits & Filings

JOHNSON & JOHNSON 8-K Report, Material Agreement (May 2, 2011)

Filed May 2, 2011For Securities:JNJ

Summary

Johnson & Johnson has entered into a definitive agreement to acquire Synthes, Inc., a Swiss medical device company, in a cash and stock transaction. The acquisition is structured as a merger where a J&J subsidiary will merge with Synthes, with Synthes continuing as the surviving entity. This strategic move signals J&J's intent to bolster its medical device portfolio, likely targeting growth in areas where Synthes has a strong presence. The transaction is subject to customary closing conditions, including regulatory approvals and Synthes shareholder approval, with significant shareholders already committed to supporting the deal. The deal terms outline a mixed consideration for Synthes shareholders, comprising a fixed cash component and a variable stock component, with specific price ranges for J&J's common stock that influence the final exchange ratio. This structure introduces some pricing flexibility for J&J. The agreement also includes mutual termination fees, indicating the seriousness of the commitment and the potential costs associated with deal failure. Investors should monitor the progress of regulatory reviews and Synthes shareholder vote for key milestones.

Key Highlights

  • 1Johnson & Johnson to acquire Synthes, Inc. in a cash and stock merger.
  • 2Acquisition aims to expand J&J's medical device offerings.
  • 3Consideration for Synthes shareholders includes CHF 55.65 in cash and a variable amount of J&J common stock.
  • 4The value of the stock component is subject to J&J's volume-weighted average trading price over a specific period, with a defined price range.
  • 5Key Synthes shareholders, representing approximately 37.5% of outstanding shares, have entered into a voting agreement to support the merger.
  • 6The transaction is contingent on Synthes shareholder approval, antitrust clearance (including Hart-Scott-Rodino and European Commission), and other customary closing conditions.
  • 7Both J&J and Synthes may owe a $650 million termination fee under specific circumstances.

Frequently Asked Questions

While not explicitly detailed in this 8-K filing, the acquisition of Synthes, a medical device company, is expected to enhance Johnson & Johnson's presence and offerings within the medical device sector. This is a common strategy for large healthcare conglomerates to strengthen specific business segments and expand market share.

Synthes shareholders will receive a combination of cash and Johnson & Johnson common stock. Specifically, each share of Synthes common stock will be converted into CHF 55.65 in cash, plus a variable number of J&J shares. The value of the stock component is tied to J&J's stock price, with defined mechanisms to adjust the number of shares exchanged based on J&J's average trading price during a specified period.

The merger is subject to several conditions, including the approval of Synthes' stockholders, clearance from antitrust authorities such as the Hart-Scott-Rodino Act and the European Commission, and other standard closing conditions typical for mergers and acquisitions.

The filing mentions customary termination rights for both parties and a mutual termination fee of $650 million if the agreement is terminated under certain circumstances. This indicates potential financial implications if the deal does not close. Key conditions like regulatory approvals and shareholder votes also represent potential hurdles.